Y-mAbs Therapeutics, a Phase 2 biotech developing monoclonal antibody therapies for pediatric cancers, filed on Friday with the SEC to raise up to $92 million in an initial public offering.
The New York, NY-based company was founded in 2015 and plans to list on the Nasdaq under the symbol YMAB. Y-mAbs Therapeutics filed confidentially on February 13, 2018. BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
